Asklepios BioPharmaceutical: Funding, Investors & Team (Oct 2026)
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders and other rare diseases. It offers proprietary AAV technology, manufacturing capabilities, and a robust pipeline of in-house clinical programs for clients in the medical biopharmaceutical industry. Its pipeline includes clinical-stage programs in Pompe disease and congestive heart failure and a diverse preclinical portfolio of therapeutics targeting neuromuscular, CNS, and other diseases, as well as out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. The company’s gene therapy platform includes Pro10, an industry-leading proprietary cell line manufacturing process, and an extensive AAV capsid, and promoter library. Asklepios BioPharmaceutical was founded in 2001 and is headquartered in Research Triangle Park, North Carolina.
Asklepios BioPharmaceutical has raised $2.0M across 1 funding round on record, the most recent an undisclosed round of $2.0M announced in Sep 2020.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Asklepios BioPharmaceutical Company Profile and Key Stats
Latest funding round on record: Sep 2020.
Asklepios BioPharmaceutical Funding Rounds
Asklepios BioPharmaceutical Founders and Leadership Team
Contact details for the Asklepios BioPharmaceutical team: 1 of 1 has an email address on file.
Start 14-day free trial →Asklepios BioPharmaceutical Funding Compared to Other Biotechnology Startups
Asklepios BioPharmaceutical's latest round of $2.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Asklepios BioPharmaceutical in Biotechnology and Chapel Hill
Companies Similar to Asklepios BioPharmaceutical
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Asklepios BioPharmaceutical Funding FAQs
What does Asklepios BioPharmaceutical do?
Asklepios BioPharmaceutical is a biotechnology company developing adeno-associated virus (AAV) gene therapies for genetic disorders and other rare diseases. It offers proprietary AAV technology, manufacturing capabilities, and a robust pipeline of in-house clinical programs for clients in the medical biopharmaceutical industry. Its pipeline includes clinical-stage programs in Pompe disease and congestive heart failure and a diverse preclinical portfolio of therapeutics targeting neuromuscular, CNS, and other diseases, as well as out-licensed clinical indications for hemophilia and Duchenne muscular dystrophy. The company’s gene therapy platform includes Pro10, an industry-leading proprietary cell line manufacturing process, and an extensive AAV capsid, and promoter library. Asklepios BioPharmaceutical was founded in 2001 and is headquartered in Research Triangle Park, North Carolina.
How much funding has Asklepios BioPharmaceutical raised?
Asklepios BioPharmaceutical has raised $2.0M across 1 round on record. The most recent is an undisclosed round of $2.0M announced in Sep 2020.
When did Asklepios BioPharmaceutical last raise funding?
Asklepios BioPharmaceutical's most recent funding round on record is an undisclosed round of $2.0M, announced in Sep 2020.
Who is the CEO of Asklepios BioPharmaceutical?
Sheila Mikhail is listed as CEO at Asklepios BioPharmaceutical.
Where is Asklepios BioPharmaceutical headquartered?
Asklepios BioPharmaceutical is based in Chapel Hill, North Carolina, United States.
How many employees does Asklepios BioPharmaceutical have?
Asklepios BioPharmaceutical is in the 101-250 employee band.
How does Asklepios BioPharmaceutical's funding compare to other Biotechnology startups?
Asklepios BioPharmaceutical's latest round of $2.0M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Asklepios BioPharmaceutical Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Asklepios BioPharmaceutical is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.